Tag: primary biliary cholangitis
Gilead Sciences completes $4.3bn acquisition of CymaBay Therapeutics to enhance liver disease portfolio
Gilead Sciences, Inc. (Nasdaq: GILD) has officially announced the successful acquisition of CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for a staggering $4.3 billion, a move that ... Read More
Gilead Sciences to acquire CymaBay Therapeutics to enhance liver disease portfolio
In a significant move within the biopharmaceutical industry, Gilead Sciences, Inc. (Nasdaq: GILD) has confirmed its acquisition of CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for a ... Read More
Lupin obtains FDA approval for generic version of Ocaliva Tablets
Indian pharmaceutical company Lupin has announced its approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for Obeticholic ... Read More
Lupin bags tentative approval for Ocaliva Tablets generic in US
Lupin said that it has been issued tentative approval for Obeticholic Acid Tablets, 5 mg and 10 mg from the US Food and Drug Administration ... Read More
Cadila Healthcare gets FDA nod for phase 2(b)/3 trial of saroglitazar magnesium
Cadila Healthcare (Zydus Cadilla) said that it has obtained permission from the US Food and Drug Administration (FDA) to launch the phase 2(b)/3 clinical trial ... Read More
GENFIT begins phase 3 trial of elafibranor in primary biliary cholangitis
GENFIT has started the phase 3 ELATIVE clinical trial for evaluating the efficacy and safety of elafibranor for the treatment of primary biliary cholangitis (PBC). ... Read More